medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2013, Número 3

<< Anterior Siguiente >>

Ann Hepatol 2013; 12 (3)


Serum natremia affects health-related quality of life in patients with liver cirrhosis: a prospective, single centre study

Wunsch E, Naprawa G, Koziarska D, Milkiewicz M, Nowacki P, Milkiewicz P

Idioma: Ingles.
Referencias bibliográficas: 37
Paginas: 448-455
Archivo PDF: 233.09 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Les I, Doval E, Flavia M, Jacas C, Cardenas G, Esteban R, Guardia J, et al. Quality of life in cirrhosis is related to potentially treatable factors. Eur J Gastroenterol Hepatol 2010; 22: 221-7.

  2. Eisenmenger WJ, Blondheim SH, Bongiovanni AM, Kunkel HG. Electrolyte studies on patients with cirrhosis of the liver. J Clin Invest 1950; 29: 1491-9.

  3. Brandman D, Biggins SW, Hameed B, Roberts JP, Terrault NA. Pretransplant severe hepatic encephalopathy, peritransplant sodium and post-liver transplantation morbidity and mortality. Liver Int 2012; 32: 158-64.

  4. Dawwas MF, Lewsey JD, Neuberger JM, Gimson AE. The impact of serum sodium concentration on mortality after liver transplantation: a cohort multicenter study. Liver Transpl 2007; 13: 1115-24.

  5. Heuman DM, Abou-Assi SG, Habib A, Williams LM, Stravitz RT, Sanyal AJ, Fisher RA, et al. Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology 2004; 40: 802-10.

  6. Londono MC, Guevara M, Rimola A, Navasa M, Taura P, Mas A, Garcia-Valdecasas JC, et al. Hyponatremia impairs early posttransplantation outcome in patients with cirrhosis undergoing liver transplantation. Gastroenterology 2006; 130: 1135-43.

  7. Londono MC, Cardenas A, Guevara M, Quinto L, de Las HD, Navasa M, Rimola A, et al. MELD score and serum sodium in the prediction of survival of patients with cirrhosis awaiting liver transplantation. Gut 2007; 56: 1283-90.

  8. Ruf AE, Kremers WK, Chavez LL, Descalzi VI, Podesta LG, Villamil FG. Addition of serum sodium into the MELD score predicts waiting list mortality better than MELD alone. Liver Transpl 2005; 11: 336-43.

  9. Gines P, Guevara M. Hyponatremia in cirrhosis: pathogenesis, clinical significance, and management. Hepatology 2008; 48: 1002-10.

  10. Gines A, Escorsell A, Gines P, Salo J, Jimenez W, Inglada L, Navasa M, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993; 105: 229-36.

  11. Dawwas MF, Lewsey JD, Watson CJ, Gimson AE. The impact of serum potassium concentration on mortality after liver transplantation: a cohort multicenter study. Transplantation 2009; 88: 402-10.

  12. Gines P, Wong F, Smajda Lew E, Diamand F. Hyponatremia is a major determinant of impaired health-related quality of life in cirrhosis with ascites. Hepatology 2007; 46: 567A [abstract].

  13. Sola E, Watson H, Graupera I, Turon F, Barreto R, Rodriguez E, et al. Factors related to quality of life in patients with cirrhosis and ascites: Relevance of serum sodium concentration and leg edema. J Hepatol 2012. Doi:http:// dx.doi.org/10.1016/j.jhep.2012.07.020

  14. Schomerus H. Quality of life in cirrhotics with minimal hepatic encephalopathy. Metab Brain Dis 2001; 16: 37-41.

  15. Wunsch E, Szymanik B, Post M, Marlicz W, Mydlowska M, Milkiewicz P. Minimal hepatic encephalopathy does not impair health-related quality of life in patients with cirrhosis: a prospective study. Liver Int 2011; 31: 980-4.

  16. Moscucci F, Nardelli S, Pentassuglio I, Pasquale C, Ridola L, Merli M, Riggio O. Previous overt hepatic encephalopathy rather than minimal hepatic encephalopathy impairs healthrelated quality of life in cirrhotic patients. Liver Int 2011; 31: 1505-10.

  17. Younossi ZM, Guyatt G, Kiwi M, Boparai N, King D. Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease. Gut 1999; 45: 295-300.

  18. Ware JE Jr., Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: 473-83.

  19. Conn HO, Leevy CM, Vlahcevic ZR, Rodgers JB, Maddrey WC, Seeff L, Levy LL. Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial. Gastroenterology 1977; 72: 573-83.

  20. Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT. Hepatic encephalopathy-definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 2002; 35: 716-21.

  21. Romero-Gomez M. Critical flicker frequency: it is time to break down barriers surrounding minimal hepatic encephalopathy. J Hepatol 2007; 47: 10-1.

  22. Weissenborn K. Minimal hepatic encephalopathy: a permanent source of discussion. Hepatology 2002; 35: 494-6.

  23. Randolph C, Hilsabeck R, Kato A, Kharbanda P, Li YY, Mapelli D, Ravdin LD, et al. Neuropsychological assessment of hepatic encephalopathy: ISHEN practice guidelines. Liver Int 2009; 29: 629-35.

  24. Weissenborn K, Ennen JC, Schomerus H, Ruckert N, Hecker H. Neuropsychological characterization of hepatic encephalopathy. J Hepatol 2001; 34: 768-73.

  25. Amodio P, Campagna F, Olianas S, Iannizzi P, Mapelli D, Penzo M, Angeli P, et al. Detection of minimal hepatic encephalopathy: normalization and optimization of the Psychometric Hepatic Encephalopathy Score. A neuropsychological and quantified EEG study. J Hepatol 2008; 49: 346-53.

  26. Curran S, Wattis J. Critical flicker fusion threshold: a potentially useful measure for the early detection of Alzheimer’s disease. Hum Psychopharmacol 2000; 15: 103-12.

  27. Kircheis G, Wettstein M, Timmermann L, Schnitzler A, Haussinger D. Critical flicker frequency for quantification of low-grade hepatic encephalopathy. Hepatology 2002; 35: 357-66.

  28. Romero-Gomez M, Cordoba J, Jover R, del Olmo JA, Ramirez M, Rey R, de ME, et al. Value of the critical flicker frequency in patients with minimal hepatic encephalopathy. Hepatology 2007; 45: 879-85.

  29. Sharma P, Sharma BC, Puri V, Sarin SK. Critical flicker frequency: diagnostic tool for minimal hepatic encephalopathy. J Hepatol 2007; 47: 67-73.

  30. Kircheis G, Wettstein M, Timmermann L, Schnitzler A, Haussinger D. Critical flicker frequency for quantification of low-grade hepatic encephalopathy. Hepatology 2002; 35: 357-66.

  31. Gines P, Berl T, Bernardi M, Bichet DG, Hamon G, Jimenez W, Liard JF, et al. Hyponatremia in cirrhosis: from pathogenesis to treatment. Hepatology 1998; 28: 851-64.

  32. Angeli P, Wong F, Watson H, Gines P. Hyponatremia in cirrhosis: Results of a patient population survey. Hepatology 2006; 44: 1535-42.

  33. Prakash RK, Mullen KD. Is poor quality of life always present with minimal hepatic encephalopathy? Liver Int 2011; 31: 908-10.

  34. Groeneweg M. Subclinical hepatic encephalopathy impairs daily functioning. Hepatology 1998; 28: 45-9.

  35. Weissenborn K: PHES: one label, different goods?! J Hepatol 2008; 49: 308-312.

  36. Weissenborn K, Heidenreich S, Ennen J, Ruckert N, Hecker H. Attention deficits in minimal hepatic encephalopathy. Metab Brain Dis 2001; 16: 13-9.

  37. Bajaj JS, Wade JB, Sanyal AJ. Spectrum of neurocognitive impairment in cirrhosis: Implications for the assessment of hepatic encephalopathy. Hepatology 2009; 50: 2014-21.




2020     |     www.medigraphic.com